The present study involves the development of certain thiazolo[3,2-a]pyrimidin-5-ones linked through an ethylene bridge to various amines. The newly synthesized compounds 4-6(a-c) were subjected to in vitro anticancer evaluation using NCI antitumor screening. The target compounds showed observed activity against Renal UO-31 cancer cell line with cell growth promotion 52.72%-64.52%. Assessment of toxicities, druglikeness, and drug score profiles are reported. Some of the synthesized compounds showed good docking scores with potential anticancer targets. In vitro anticancer evaluation, together with in silico studies, revealed that compounds 5c, 4a, and 4b could be considered as promising leads for further development of more potent anticancer agents.